Changes in the Treatment Strategies for Helicobacter pylori Infection in Children and Adolescents in Korea
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
The policies developed for the treatment of Helicobacter pylori infection in adults may not be the most suitable ones to treat children and adolescents. Methods used to treat children and adolescents in Europe and North America may not be appropriate for treating children and adolescents in Korea due to differences in epidemiological characteristics of H. pylori between regions. Moreover, the agreed standard guidelines for the treatment of H. pylori infection in children and adolescents in Korea have not been established yet. In this study, the optimal treatment strategy for H. pylori infection control in children and adolescents in Korea is discussed based on these guidelines, and recent progress on the use and misuse of antimicrobial agents is elaborated. Non-invasive as well as invasive diagnostic test and treatment strategy for H. pylori infection are not recommendable in children aged less than ten years or children with body weight under 35 kg, except in cases of clinically suspected or endoscopically identified peptic ulcers. The uncertainty, whether enough antimicrobial concentrations to eradicate H. pylori can be maintained when administered according to body weight-based dosing, and the costs and adverse effects outweighing the anticipated benefits of treatment make it difficult to decide to eradicate H. pylori in a positive noninvasive diagnostic test in this age group. However, adolescents over ten years of age or with a bodyweight of more than 35 kg can be managed aggressively as adults, because they can tolerate the adult doses of anti-H. pylori therapy. In adolescents, the prevention of future peptic ulcers and gastric cancers is expected after the eradication of H. pylori. Bismuth-based quadruple therapy (bismuth-proton pump inhibitor-amoxicillin/tetracycline-metronidazole) with maximal tolerable doses and optimal dose intervals of 14 days is recommended, because in Korea, the antibiotic susceptibility test for H. pylori is not performed at the initial diagnostic evaluation. If the first-line treatment fails, concomitant therapy plus bismuth can be attempted for 14 days as an empirical rescue therapy. Finally, the salvage therapy, if needed, must be administered after the H. pylori antibiotic susceptibility test.
Abstract
The policies developed for the treatment of Helicobacter pylori infection in adults may not be the most suitable ones to treat children and adolescents. Methods used to treat children and adolescents in Europe and North America may not be appropriate for treating children and adolescents in Korea due to differences in epidemiological characteristics of H. pylori between regions. Moreover, the agreed standard guidelines for the treatment of H. pylori infection in children and adolescents in Korea have not been established yet. In this study, the optimal treatment strategy for H. pylori infection control in children and adolescents in Korea is discussed based on these guidelines, and recent progress on the use and misuse of antimicrobial agents is elaborated. Non-invasive as well as invasive diagnostic test and treatment strategy for H. pylori infection are not recommendable in children aged less than ten years or children with body weight under 35 kg, except in cases of clinically suspected or endoscopically identified peptic ulcers. The uncertainty, whether enough antimicrobial concentrations to eradicate H. pylori can be maintained when administered according to body weight-based dosing, and the costs and adverse effects outweighing the anticipated benefits of treatment make it difficult to decide to eradicate H. pylori in a positive noninvasive diagnostic test in this age group. However, adolescents over ten years of age or with a bodyweight of more than 35 kg can be managed aggressively as adults, because they can tolerate the adult doses of anti-H. pylori therapy. In adolescents, the prevention of future peptic ulcers and gastric cancers is expected after the eradication of H. pylori. Bismuth-based quadruple therapy (bismuth-proton pump inhibitor-amoxicillin/tetracycline-metronidazole) with maximal tolerable doses and optimal dose intervals of 14 days is recommended, because in Korea, the antibiotic susceptibility test for H. pylori is not performed at the initial diagnostic evaluation. If the first-line treatment fails, concomitant therapy plus bismuth can be attempted for 14 days as an empirical rescue therapy. Finally, the salvage therapy, if needed, must be administered after the H. pylori antibiotic susceptibility test.
참고문헌 (40)
- Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
- 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013", 대한소화기학회지, 62(1), pp.3~26 (2013), 대한소화기학회
- Jones NL, "Joint ESPGHAN", NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents(update 2016), 2017, pp.64, 991~1003
- Helicobacter pylori eradication as a strategy for preventing gastric cancer, "IARC Helicobacter pylori Working Group", International Agency for Research on Cancer, ~ (2014)
- Kato M, "Guidelines for the management of Helicobacter pylori infection in Japan : 2016 revised edition", Helicobacter, 24, pp.e12597~ (2019)
- Honma H, "Clinical features of Helicobacter pylori antibody-positive junior high school students in Nagano Prefecture, Japan", Helicobacter, 24, pp.e12559~ (2019)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Graham DY, "Rational Helicobacter pylori therapy : evidence-based medicine rather than medicine-based evidence", Clin Gastroenterol Hepatol, 12, pp.177~186 (2014)
- 서지현, "Comparison of the Antibiotic Resistance of Helicobacter pylori Isolated in Jinju Over a 15-year Period", Journal of Bacteriology and Virology, 42(4), pp.305~312 (2012), 대한미생물학회[DOI]
- Seo JH, "Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea", Pediatr Int, 55, pp.332~336 (2013)
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)
- Chey WD, "ACG clinical guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
- Okuda M, "Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan", Pediatr Int, 59, pp.57~61 (2017)
- Ji-Hyun Seo, "Diagnosis of Helicobacter pylori Infection in Children and Adolescents in Korea", Pediatric Gastroenterology, Hepatology & Nutrition, 21(4), pp.219~233 (2018), 대한소아소화기영양학회
- Rhee KH, "Prevalence of Helicobacter pylori infection in Korea", J Korean Soc Microbiol, 25, pp.475~490 (1990)
- Borody TJ, "Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication", Med J Aust, 151, pp.431~435 (1989)
- Drumm B, "Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin", J Pediatr, 113, pp.908~912 (1988)
- Oderda G, "Amoxycillin plus tinidazole for Campylobacter pylori gastritis in children : assessment by serum IgG antibody, pepsinogen I, and gastrin levels", Lancet, 1, pp.690~692 (1989)
- Israel DM, "Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children", J Pediatr, 123, pp.53~58 (1993)
- Park C, "Chemotherapy of Helicobacter pylori infection", J Kor Soc Microbiol, 29, pp.421~435 (1994)
- Choi MB, "Histopathological changes of gastroduodenal mucosa after chemotherapy of Helicobacter pylori-chronic gastritis", Korean J Gastroenterol, 29, pp.41~52 (1997)
- Graham DY, "New concepts of resistance in the treatment of Helicobacter pylori infections", Nat Clin Pract Gastroenterol Hepatol, 5, pp.321~331 (2008)
- Bae SH, "Therapeutic efficacy of dual therapy and triple therapy for Helicobacter pylori infection in children", J Korean Pediatr Soc, 41, pp.323~330 (1998)
- Jungi Choi, "Efficacy of Two Triple Eradication Regimens in Children with Helicobacter pylori Infection", Journal of Korean Medical Science, 21(6), pp.1037~1040 (2006), 대한의학회
- Jeana Hong, "Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children", Pediatric Gastroenterology, Hepatology & Nutrition, 15(4), pp.237~242 (2012), 대한소아소화기영양학회
- 최인경, "소아에서 Omeprazole, Amoxicillin, Clarithromycin 삼제 병합 요법의 치료기간별 Helicobacter pylori 제균율", Pediatric Gastroenterology, Hepatology & Nutrition, 5(1), pp.19~25 (2002), 대한소아소화기영양학회
- 윤종혁, "우리나라 소아 Helicobacter pylori 감염 제균 치료 경험: 파일럿 조사 연구", Korean Journal of Helicobacter Upper Gastrointestinal Research, 17(4), pp.195~199 (2017), 대한상부위장관ㆍ헬리코박터학회[DOI]
- Gisbert JP, "Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies", Helicobacter, 22, pp.e12392~ (2017)
- Graham DY, "Helicobacter pylori therapy : a paradigm shift", Expert Rev Anti Infect Ther, 14, pp.577~585 (2016)
- Graham DY, "Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies", Expert Rev Anti Infect Ther, 16, pp.679~687 (2018)
- Li H, "Systems approaches for unveiling the mechanism of action of bismuth drugs : new medicinal applications beyond Helicobacter pylori infection", Acc Chem Res, 52, pp.216~227 (2019)
- Leussink BT, "Bismuth overdosing-induced reversible nephropathy in rats", Arch Toxicol, 74, pp.745~754 (2001)
- You-Sook Youn, "Mycoplasma pneumoniae pneumonia in children", Clinical and Experimental Pediatrics, 55(2), pp.42~47 (2012), 대한소아청소년과학회
- Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
- Choe JW, "Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea", Helicobacter, 23, pp.e12466~ (2018)
- Graham DY, "How to Effectively use bismuth quadruple therapy : the good, the bad, and the ugly", Gastroenterol Clin North Am, 44, pp.537~563 (2015)
- Furuta T, "Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy", J Clin Pharmacol, 54, pp.258~266 (2014)
- Ahn HS, "(Hong Chang-Yee) Pediatrics", pp.554~555 (2016), MiraeN
- 이은, "Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children", Clinical and Experimental Pediatrics, 60(5), pp.151~157 (2017), 대한소아청소년과학회